Morphological and biochemical basis of centchroman as a novel antineoplastic agent in MCF-7 human breast cancer cells

Indian Journal of Pharmacology

Volumn 36, Issue 4, 2004, Pages 238-243

  Srivastava, S ^a   Sharma, R ^a   Balapure, Anil K ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

17 estradiol; Centchroman; Neoplastic; Tamoxifen

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC AGENT; CATHEPSIN D; CENTCHROMAN; ESTRADIOL; LIGAND; TAMOXIFEN; TRYPAN BLUE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL COUNT; CELL STRAIN MCF 7; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; GENE EXPRESSION; HORMONE RESPONSE; HUMAN; HUMAN CELL; INCUBATION TIME; PHASE CONTRAST MICROSCOPY; SPECTROPHOTOMETRY;

EID: 4444335569     PISSN: 02537613     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Westley B, Rochefort H. A secreted glycoprotein-induced by estrogen in human breast cancer cell lines. Cell 1980;20:353-62.
2. Saxena AK, Ramchandani S, Dwivedi A, Sharma R, Bajpai VK, Bhardwaj KR, et al. Simplified cryopreservation of mammalian cell lines. In Vitro Cell Dev Biol Anim 1995; 31:326-9.
3. Seo HS, Leclercq G. Evaluation of potential implication of membrane estrogen binding sites on ERE-dependent transcriptional activity and intracellular estrogen receptor-α regulation in MCF-7 breast cancer cells. J Steroid Biochem Mol Biol 2002;80:109-23.
4. Levinson AS, Jordan VC. MCF-7: The first hormone-responsive breast cancer cell line. Cancer Res 1997; 57:3071-8.
5. Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer. Cancer Res 1990;50:4177-89.
6. Muss HB. Endocrine therapy for advanced breast cancer: A review. Breast Cancer Res Treat 1992;21:15-26.
7. Jordan VC. Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res Treat 1994;31:41-52.
8. Rochefort H, Garcia M, Glondu M, Laurent V, Liaudet E, Rey JM, et al. Cathepsin D in breast cancer: Mechanisms and clinical applications, a 1999 overview. Clin Chim Acta 2000;291:157-70.
9. Rochefort H. Cathepsin D in breast cancer. Breast Cancer Res Treat 1990;16:3-13.
10. Klijn JGM, Berns PMJJ, Dorssers LCJ, Foekens JA. Molecular markers of resistance to endocrine treatment of breast cancer. In: Dickson RB, Lippman ME, editors. Drug and hormonal resistance in breast cancer: Cellular and molecular mechanisms. UK: Ellis Horwood Chichester; 1995.
11. Macgregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 1998;50:151-96.
12. Soto AM, Sonnenschein C. The role of estrogens on the proliferation of human breast tumor cells (MCF-7). J Steroid Biochem 1985;23: 87-94.
13. Touitou I, Cavailles V, Garcia M, Defrenne A, Rochefort H. Differential regulation of cathepsin D by sex steroids in mammary cancer and uterine cells. Mol Cell Endocrinol 1989;66:231-8.
14. Zhang CC, Shapiro DJ. Activation of the p38 mitogen-activated protein kinase pathway by estrogen or by 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis. J Biol Chem 2000;275:479-86.
15. Barrett AJ, Heath MF. Lysosomal enzymes. In: Dingle JT, editor. Lysosomes: A Laboratory Handbook. Amsterdam, North Holland: Biochemical Press; 1977.
16. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with folin phenol reagent. J Biol Chem 1951;193:265-75.
17. Lobenhofer EK, Marks JR. Estrogen-induced mitogenesis of MCF-7 cells does not require the induction of mitogen-activated protein kinase activity. J Steroid Biochem Mol Biol 2000;75:11-20.
18. Lippman M, Bolan G, Huff K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 1976;36:4595-601.
19. Rochefort H, Capony F, Garcia M, Cavilles V, Freiss G, Chambon M, at al. Estrogen-induced lysosomal proteases secreted by breast cancer cells: A role in carcinogenesis? J Cell Biochem 1987;35:17-29.
20. Balapure AK, Sharma R. Regulation of gene expression of Cathepsin-D in MCF-7 cells. 31st Indian Pharmacological Society meeting. Lucknow, India. 18-20 Dec, 1998.
21. Westley BR, Holzel F, May FE. Effects of estrogen and antiestrogens, tamoxifen and LY 117, 018 on four estrogen regulated RNAs in the EFM-19 breast cancer cell line. J Steroid Biochem 1989;32:365-72.
22. May FE, Westley BR. Effect of tamoxiten and 4-hydroxytamoxifen on the pNR-1 and pNR-2 estrogen-regulated RNAs in human breast cancer cells. J Biol Chem 1987;262:15894-9.
23. Chalbos D, Philips A, Galtier F, Rochefort H. Synthetic antiestrogens modulate induction of pS2 and cathepsin-D messenger ribonucleic acid by growth factors and adenosine 3′,5′ -monophosphate in MCF7 cells. Endocrinology 1993;133:571-6.
24. Wisel MS, Datta A Saxena RN. Effect of antiestrogens on early pregnancy in guinea pigs. Int J Fertil Menopausal Stud 1994;39:156-63.
25. Srivastava AK, Agnihotri A, Kamboj VP. Binding of centchroman - a nonsteroidal antifertility agent to human plasma proteins. Experientia 1984;40:465-6.
26. Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 2001;53:25-71.
27. Perry RR, Kang Y, Greaves B. Effect of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann Surg Oncol 1995;2:238-45.
28. Ravdin PM. Evaluation of cathepsin D as a prognostic factor in breast cancer. Breast Cancer Res Treat 1993;24:219-26.
29. Bidere N, Lerenzo HK, Carmona S, Laforge M, Harper F, Dumont C, et al. Cathepsin D triggers bax activation, resulting in selective apoptosis - inducing-factor (AIF) relocation in T lymphocytes entering the early commitment phase to apoptosis. J Biol Chem 2003;278: 31401-11.